Weight
Mazdutide
Metabolic
31
Amino acids
Molecular weight
Peptide
Type
First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control.
Top researched benefits
Overview of Mazdutide
Dual agonist activation: GLP-1 stimulates insulin, suppresses glucagon, slows gastric emptying; Glucagon increases energy expenditure and thermogenesis while GLP-1 counteracts glucose-raising effects.
Weight Loss
- GLORY-2 demonstrated 20.1% weight loss with 9mg over 60 weeks; 48.7% achieved ≥20% reduction.
- Significant reductions in waist circumference, systolic BP (-7.57 mmHg), triglycerides (-43%).
- Exploratory analysis showed 80.2% reduction in liver fat, suggesting MASLD/MASH benefits.
Type 2 Diabetes
- HbA1c reductions of 1.41-2.03% across trials; DREAMS-3 showed -2.03% vs semaglutide -1.84%.
- 48% achieved HbA1c <7.0% AND ≥10% weight loss versus 21% with semaglutide.
Cardiovascular
- Systolic reduction of -7.57 mmHg, diastolic -2.98 mmHg in clinical trials.
- Total cholesterol -16.82%, triglycerides -43.29%, LDL -17.07%.
Storage
Refrigerate reconstituted solution at 2-8°C, use within 30 days; lyophilized powder at -20°C until reconstitution
Frequency
Once weekly injection
Typical Dose
Start 1.5-3mg weekly, titrate up to 6-9mg based on response
Cycle Duration
48-60+ weeks for optimal results per clinical trials
Chemical Makeup
Key benefits
Up to 20% body weight loss
Superior glycemic control versus semaglutide
Increased energy expenditure via glucagon receptor activation
Improved cardiometabolic markers (BP, lipids, liver fat)
Once-weekly injection convenience
Community interest
This peptide is still gaining traction in the community.
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesMazdutide Molecular Information
View the scientifc details of Mazdutide.
31
Amino Acids
Mazdutide
Ala
Ala
Position 6
Cys
Cys
Position 7
Ile
Ile
Position 8
Asp
Asp
Position 9
Leu
Leu
Position 10
Ile
Ile
Position 11
Asn
Asn
Position 12
Glu
Glu
Position 13
Ala
Ala
Position 14
Arg
Arg
Position 15
Ser
Ser
Position 16
Tyr
Tyr
Position 17
Asn
Asn
Position 18
Thr
Thr
Position 19
His
His
Position 20
Glu
Glu
Position 21
Thr
Thr
Position 22
Ile
Ile
Position 23
Cys
Cys
Position 24
Pro
Pro
Position 25
Glu
Glu
Position 26
Pro
Pro
Position 27
Thr
Thr
Position 28
Ile
Ile
Position 29
Asp
Asp
Position 30
Glu
Glu
Position 31
Ala
Ala
Position 1
Met
Met
Position 2
Ile
Ile
Position 3
Asn
Asn
Position 4
Pyl
Pyl
Position 5
Molecular Weight
4DaChain Length
31Amino AcidsType
PeptideMazdutide Protocols
Subcutaneous injection delivering dual GLP-1/glucagon agonism with once-weekly dosing enabled by fatty acid conjugation.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Weight loss initiation (3mg target) | 1.5 | 1 week range | SubQ |
| Weight loss progression (4.5mg target) | 1.5 | 1 week range | SubQ |
| Weight loss optimization (6mg target) | 2 | 1 week range | SubQ |
| Maximum weight loss (9mg target) | 3 | 1 week range | SubQ |
| T2D management (mild-moderate) | 3 | 1 week range | SubQ |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Allow vial to reach room temperature (15-20 minutes)
- Clean vial top with alcohol swab, air dry completely
- Calculate reconstitution volume for desired concentration
- Draw bacteriostatic water into syringe, remove air bubbles
- Inject BAC water slowly down vial side—drop by drop to prevent foaming
- Gently swirl vial in circular motion
- Verify complete clarity and colorless appearance
- Label vial with reconstitution date and concentration
- Store at 2-8°C, use within 30 days
Mazdutide Cycle
The Mazdutide Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 1-2
- Appetite reduction, possible mild nausea, decreased portion sizes
- Week 3-4
- Early weight loss begins (1-2%), improved satiety after meals
- Week 4-8
- Dose escalation phase, GI symptoms typically improving, 3-5% weight loss
- Week 8-16
- Steady weight loss continues (7-12%), energy expenditure effects evident
- Week 16-32
- Significant weight reduction (12-17%), metabolic markers improving
- Week 32-60
- Peak effects (up to 20% weight loss), sustained improvements in BP, lipids, glucose
Dosing tools
Mazdutide Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
0.3mL / 30 units
5 units
0.050 mL
1 mL
2 mL
3 mL
5 mL
Custom
Conversion: 1,000 mcg = 1 mg
Injection Results
Based on your vial and dilution inputs.
Safe concentration range
Mazdutide
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Mazdutide vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
Research Purposes Only
These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.
Reference Guide
Dosing Cycle
- Peptide
- Mazdutide
- Dosing
- Start 1.5-3mg weekly, titrate up to 6-9mg based on response
- Dosing Frequency
- Once weekly injection
- Cycle Duration
- 48-60+ weeks for optimal results per clinical trials
- Storage
- Refrigerate reconstituted solution at 2-8°C, use within 30 days; lyophilized powder at -20°C until reconstitution
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of Mazdutide interactions with other common peptides and substances.
Healing
bpc
Longevity
BPC-157
COMPATIBLE
No known interactions; may support gut health and potentially reduce GI side effects.
Weight
sem
Metabolic
Semaglutide
AVOID
Both are GLP-1 agonists; combining increases hypoglycemia and severe GI side effect risk.
Weight
tir
Metabolic
Tirzepatide
AVOID
Both target GLP-1 receptor; additive effects on GI symptoms and hypoglycemia risk.
Side effects
Avoid: Do not take Mazdutide with Semaglutide, Tirzepatide.
Contraindications
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome history (class warning for GLP-1 agonists)
Pregnancy or breastfeeding (insufficient safety data)
Stop signs
Severe or persistent abdominal pain (potential pancreatitis)
Neck lumps, hoarseness, or difficulty swallowing
Severe nausea/vomiting preventing adequate nutrition or hydration
Signs of severe hypoglycemia (confusion, sweating, shakiness)
Severe allergic reactions (rash, difficulty breathing, facial swelling)
Unusual mood changes, depression, or suicidal thoughts
Signs of gallbladder problems (severe upper right abdominal pain)
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What benefits can peptides offer in research?
Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.
What are some exciting applications of peptides in modern science?
Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.
How do peptides influence health and wellness?
Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.
Where can I find the latest studies on peptide applications?
Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.
Are there any guidelines for using peptides in research?
Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.
What is the difference between peptides and proteins?
Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.
How should peptides be stored?
Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.
Can peptides be taken orally?
Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.
MazdutideResearch References
Mazdutide is an extensively studied compound
Mazdutide
Mazdutide is an extensively studied compound
GLORY-1 Phase 3 Trial
610 Chinese adults with obesity/overweight; 48 weeks. First Phase 3 weight management trial showing clinically meaningful weight reductions. NEJM.
2025
GLORY-2 Phase 3 Trial
462 Chinese adults with obesity; 60 weeks; 9mg dose. 20.1% weight loss vs 2.8% placebo; 48.7% achieved ≥20% reduction; no plateau observed.
2025
DREAMS-3 Phase 3 Trial - Head-to-Head vs Semaglutide
349 Chinese adults with T2D and obesity; 32 weeks. Mazdutide superiority: 48% vs 21% achieved HbA1c <7.0% AND ≥10% weight reduction (p<0.0001).
2025
Phase 2 T2D Trial
Chinese adults with T2D; 20 weeks. HbA1c reductions 1.41-1.67% vs 0.03% placebo; weight loss up to 7.1%. Diabetes Care.
2024